Probiodrug AG (PBD):製薬・医療:M&Aディール及び事業提携情報

GlobalDataが発行した調査報告書(DATA904C7539)
◆英語タイトル:Probiodrug AG (PBD) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C7539
◆発行会社(リサーチ会社):GlobalData
◆発行日:2018年10月
◆ページ数:67
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:ドイツ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Summary
Probiodrug AG (Probiodrug) is a clinical stage biopharmaceutical company that conducts research and development of new medicines for the treatment of Alzheimer’s disease. The company provides three pipeline drug candidates such as PQ912, PBD-C06 and PQ1565. Its PQ912 drug candidate is a small molecule glutaminyl cyclase inhibitor in Phase II clinical trials that inhibits QC-enzyme for animal models. Probiodrug’s PBD-C06 is a monoclonal antibody under evaluation, which clear toxic pyroglutamate-Abeta in the brain. The company’s PQ1565 is a second QC inhibitor in preclinical stage and demonstrated attractive drug-like properties. It develops a therapeutic approach, dipeptidyl peptidase 4 (DP4) inhibitors for the treatment of diabetes. Probiodrug is headquartered in Halle, Germany.

Probiodrug AG (PBD) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Probiodrug AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Probiodrug AG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Probiodrug AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Probiodrug AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Probiodrug AG, Medical Devices Deals, 2012 to YTD 2018 10
Probiodrug AG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Probiodrug AG, Pharmaceuticals & Healthcare, Deal Details 12
Venture Financing 12
Probiodrug Secures US$19.5 Million In Series C Financing 12
Partnerships 14
Probiodrug to Enter into Agreement with Julius Clinical 14
Probiodrug Enters into Research Agreement with Paul-Flechsig-Institute 15
Probiodrug Enters Into Co-Development Agreement With VU University Medical Center 16
Evotec Enters Into Co-Development Agreement With Probiodrug For Glutaminyl Cyclase 17
Licensing Agreements 18
Probiodrug Extends Licensing Agreement with Crossbeta Biosciences 18
QPS Austria Enters into Licensing Agreement with Probiodrug 19
Equity Offering 20
Probiodrug Raises USD17.8 Million in Private Placement of Shares 20
Probiodrug Raises USD14.7 Million in Private Placement of Shares 22
Probiodrug Completes IPO for USD29.6 Million 23
Asset Transactions 25
AstraZeneca Acquires CDK9 Inhibitor Program From Probiodrug 25
Probiodrug AG – Key Competitors 27
Probiodrug AG – Key Employees 28
Probiodrug AG – Locations And Subsidiaries 29
Head Office 29
Other Locations & Subsidiaries 29
Recent Developments 30
Financial Announcements 30
May 15, 2018: Probiodrug reports First Quarter 2018 Business Update 30
Apr 03, 2018: Probiodrug reports full year 2017 financial results 34
Nov 30, 2017: Probiodrug reports Third Quarter 2017 Business Update 39
Aug 31, 2017: Probiodrug reports financial results for H1 2017 and corporate update 43
May 12, 2017: Probiodrug reports First Quarter 2017 Business Update 47
Mar 30, 2017: Probiodrug reports full year 2016 financial results 49
Corporate Communications 53
Oct 05, 2018: Probiodrug Reports Management Changes 53
Product News 54
05/16/2017: Probiodrug Announces Acceptance of PQ912 Pharmacology Paper by Peer Reviewed Journal 54
04/23/2018: Probiodrug Appoints Dr. Ulrich Dauer as Chief Executive Officer 55
03/28/2017: Probiodrug To Present At Alzheimers And Parkinsons Diseases Congress 56
03/16/2018: Probiodrug to Present at 255th ACS National Meeting & Exposition 57
Clinical Trials 58
Oct 26, 2017: Probiodrug to Present Data from its Phase 2a SAPHIR Study at International Alzheimer’s Disease Conference 58
Oct 16, 2017: Probiodrug initiates Phase 2b core program of PQ912 and details further strategy 59
Jun 11, 2017: Probiodrug announces encouraging results of the Phase 2a SAPHIR Study 60
Apr 10, 2017: Probiodrug to present at Huntington’s Disease Therapeutics Conference 62
Apr 07, 2017: Probiodrug Last Patient Last Visit reached in the SAPHIR Study 63
Jan 09, 2017: Probiodrug announces completion of recruitment for the SAPHIR Phase 2a study of Glutaminyl Cyclase Inhibitor PQ912 in early Alzheimer’s disease patients 64
Other Significant Developments 65
Aug 30, 2018: Probiodrug announces financial results for H1 2018 65
Appendix 67
Methodology 67
About GlobalData 67
Contact Us 67
Disclaimer 67

List of Tables
Probiodrug AG, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Probiodrug AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Probiodrug AG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Probiodrug AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Probiodrug AG, Deals By Therapy Area, 2012 to YTD 2018 9
Probiodrug AG, Medical Devices Deals, 2012 to YTD 2018 10
Probiodrug AG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Probiodrug Secures US$19.5 Million In Series C Financing 12
Probiodrug to Enter into Agreement with Julius Clinical 14
Probiodrug Enters into Research Agreement with Paul-Flechsig-Institute 15
Probiodrug Enters Into Co-Development Agreement With VU University Medical Center 16
Evotec Enters Into Co-Development Agreement With Probiodrug For Glutaminyl Cyclase 17
Probiodrug Extends Licensing Agreement with Crossbeta Biosciences 18
QPS Austria Enters into Licensing Agreement with Probiodrug 19
Probiodrug Raises USD17.8 Million in Private Placement of Shares 20
Probiodrug Raises USD14.7 Million in Private Placement of Shares 22
Probiodrug Completes IPO for USD29.6 Million 23
AstraZeneca Acquires CDK9 Inhibitor Program From Probiodrug 25
Probiodrug AG, Key Competitors 27
Probiodrug AG, Key Employees 28
Probiodrug AG, Subsidiaries 29

List of Figures
Probiodrug AG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Probiodrug AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Probiodrug AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Probiodrug AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Probiodrug AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Probiodrug AG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Probiodrug AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Probiodrug AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Probiodrug AG, Medical Devices Deals, 2012 to YTD 2018 10

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ Probiodrug AG (PBD):製薬・医療:M&Aディール及び事業提携情報(Probiodrug AG (PBD) - Pharmaceuticals & Healthcare - Deals and Alliances Profile)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆